Wyeth Sees Alavert Sales Decline In Fourth Quarter Despite Good Year
This article was originally published in The Tan Sheet
Executive Summary
Sales for Wyeth's Alavert (loratadine) totaled $81.6 mil. in 2003, its first full year on the market, following a significant drop in the fourth quarter
You may also be interested in...
Wyeth Foreign Growth Strong While Alavert Sales Pick Up At Home
Sales for Wyeth's non-sedating antihistamine Alavert (loratadine) more than quadrupled compared to the previous quarter
Loratadine Private Labelers Gain On Branded Alternatives
Private label loratadine is making market share inroads against branded Claritin (Schering-Plough) and Alavert (Wyeth)
Pfizer Looking To Consumer Division To Feed DTC Efforts
Pfizer plans to apply its experience marketing Nicorette over-the-counter to its direct-to-consumer advertising for the in-development Rx smoking cessation drug varenicline